Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADTX Aditxt	$1.04 +1.0%	$1.20	$0.81 ▼ $9,800.00	$5.18M	1.5	335,697 shs	135,760 shs
ADXS Ayala Pharmaceuticals	$0.05	$0.07	$0.02 ▼ $0.78	$2.26M	1.17	4,709 shs	18 shs
ARGSQ Argos Therapeutics	$0.05	$0.05	$0.02 ▼ $0.25	$572K	2.47	13,394 shs	N/A
CANF Can-Fite BioPharma	$0.66 -0.8%	$0.89	$0.63 ▼ $3.12	$2.34M	1.02	209,631 shs	91,392 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADTX Aditxt	0.00%	+1.96%	-17.46%	-40.23%	-99.99%
ADXS Ayala Pharmaceuticals	0.00%	-1.12%	+52.74%	+51.86%	+158.54%
ARGSQ Argos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CANF Can-Fite BioPharma	0.00%	0.00%	-34.55%	-36.38%	-70.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADTX Aditxt	0.2836 of 5 stars	0.0	4.0	0.0	0.0	0.0	0.0	0.6
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARGSQ Argos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	2.104 of 5 stars	3.5	2.0	0.0	0.0	0.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADTX Aditxt	0.00	N/A	N/A	N/A
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
ARGSQ Argos Therapeutics	0.00	N/A	N/A	N/A
CANF Can-Fite BioPharma	3.00	Buy	$14.00	2,018.00% Upside

Current Analyst Ratings Breakdown

Latest ARGSQ, ADXS, ADTX, and CANF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	CANF Can-Fite BioPharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADTX Aditxt	$130K	39.84	N/A	N/A	($1.52) per share	-0.68
ADXS Ayala Pharmaceuticals	$3.24M	0.70	N/A	N/A	($2.06) per share	-0.03
ARGSQ Argos Therapeutics	$1.90M	0.30	N/A	N/A	($1.63) per share	-0.03
CANF Can-Fite BioPharma	$674K	3.47	N/A	N/A	$1.76 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADTX Aditxt	-$34.45M	N/A	0.00	∞	N/A	-206,431.38%	-316.98%	-80.88%	N/A
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	N/A	N/A	N/A
ARGSQ Argos Therapeutics	-$40.57M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	-$7.63M	-$1.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARGSQ, ADXS, ADTX, and CANF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	ADTX Aditxt	N/A	-$3.45	N/A	-$3.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARGSQ Argos Therapeutics	N/A	N/A	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADTX Aditxt	N/A	0.02	0.02
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
ARGSQ Argos Therapeutics	N/A	N/A	N/A
CANF Can-Fite BioPharma	N/A	2.93	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADTX Aditxt	15.54%
ADXS Ayala Pharmaceuticals	7.18%
ARGSQ Argos Therapeutics	N/A
CANF Can-Fite BioPharma	21.00%

Insider Ownership

Company	Insider Ownership
ADTX Aditxt	0.01%
ADXS Ayala Pharmaceuticals	0.63%
ARGSQ Argos Therapeutics	28.21%
CANF Can-Fite BioPharma	0.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADTX Aditxt	60	4.98 million	4.98 million	No Data
ADXS Ayala Pharmaceuticals	20	42.63 million	42.36 million	Not Optionable
ARGSQ Argos Therapeutics	122	10.59 million	N/A	Not Optionable
CANF Can-Fite BioPharma	8	3.54 million	N/A	Not Optionable

ARGSQ, ADXS, ADTX, and CANF Headlines

Recent News About These Companies

Can-Fite BioPharma Ltd.: Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

July 30, 2025 | finanznachrichten.de

Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone

July 30, 2025 | finance.yahoo.com

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

July 30, 2025 | globenewswire.com

Can-Fite BioPharma Ltd.: Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

July 28, 2025 | finanznachrichten.de

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia

July 28, 2025 | finance.yahoo.com

Can-Fite BioPharma Ltd. Announces $5.0 Million Public Offering with Potential for Additional $10.0 Million in Gross Proceeds

July 28, 2025 | quiverquant.comQ

Can-Fite Announces Up To $15.0 Million Public Offering

July 28, 2025 | globenewswire.com

Can-Fite BioPharma’s Piclidenoson Shows Promise in Vascular Dementia Treatment

July 28, 2025 | tipranks.com

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

July 28, 2025 | globenewswire.com

CANF Can-Fite BioPharma Ltd. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Can-Fite BioPharma Ltd. (CANF) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston

June 16, 2025 | finance.yahoo.com

Can-Fite BioPharma says medical centers seek authorization for namodenoson

April 18, 2025 | markets.businessinsider.com

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

April 17, 2025 | globenewswire.com

Can-Fite Reports 2024 Financial Results and Clinical Update

April 14, 2025 | markets.businessinsider.com

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

April 14, 2025 | finance.yahoo.com

Can-Fite BioPharma Secures $3 Million in Direct Offering

April 14, 2025 | tipranks.com

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

April 14, 2025 | globenewswire.com

Can-Fite BioPharma Initiates Pivotal Phase 3 Study for Oral Drug Piclidenoson in Psoriasis Treatment

March 26, 2025 | nasdaq.com

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

March 24, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGSQ, ADXS, ADTX, and CANF Company Descriptions

Aditxt NASDAQ:ADTX

$1.04 +0.01 (+0.97%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$1.06 +0.02 (+2.40%)

As of 08/22/2025 07:08 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Ayala Pharmaceuticals NASDAQ:ADXS

$0.05 0.00 (0.00%)

As of 08/22/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Argos Therapeutics OTCMKTS:ARGSQ

$0.05 0.00 (0.00%)

As of 10/10/2019

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Can-Fite BioPharma NYSE:CANF

$0.66 -0.01 (-0.75%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.15%)

As of 08/22/2025 07:23 PM Eastern

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time